IDiyas

For the Inventor, By the Inventor

Muhltal, Germany

Hans-Eckart Radunz

USPTO Granted Patents = 19

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 56(Granted Patents)


Location History:

  • Darmstadt, DE (1978 - 1982)
  • Muhtal, DE (1988)
  • Muhltal, DE (1981 - 1996)

Company Filing History:

goldMedal19 out of 1,248 
 
Merck Patent Gesellschaft MIT Beschrankter Haftung
 patents

Years Active: 1978-1996

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5508390 - Diterpenes having immunomodulatory action (1996-04-16),
2. 5095114 - Process for the enantiomer-selective preparation of (1992-03-10),
3. 5026642 - Process for the enzymatic production of ketones (1991-06-25),
4. 4987133 - Salicylic acid derivatives (1991-01-22),
5. 4755592 - Statine-containing peptides useful in medicaments (1988-07-05),
6. 4733011 - New intermediates for the preparation of 13-thiaprostaglandin derivatives (1988-03-22),
7. 4680288 - Sulfur-containing 6-ketoprostaglandins (1987-07-14),
8. 4622316 - 13-thiaprostaglandins having cytoprotective activity (1986-11-11),
9. 4309441 - 13-Thiaprostaglandin derivatives (1982-01-05),
10. 4294839 - Benzothiazole derivatives and pharmaceutical formulations containing them (1981-10-13),
11. 4289768 - Phenothiazine derivatives and a process for their preparation (1981-09-15),
12. 4258047 - Pyrazole derivatives, pharmaceutical formulations thereof (1981-03-24),
13. 4210651 - Thiaprostaglandins (1980-07-01),
14. 4209444 - New prostaglandin-like diketals (1980-06-24),
15. 4188403 - Cyclopentan-1-amines (1980-02-12),

Title: Innovations and Contributions of Hans-Eckart Radunz in Pharmaceutical Patenting

Introduction: Hans-Eckart Radunz, residing in Muhltal, Germany, is a prominent inventor in the field of pharmaceuticals, holding an impressive portfolio of 19 patents. His work primarily focuses on the development of novel chemical compounds with significant therapeutic applications.

Latest Patents: Among Radunz's recent innovations are patents related to diterpenes known for their immunomodulatory effects. One such patent details the formula I, showcasing compounds where Rⁱ is structured as either --CH₂ --C(CH₃)=CH--R³ or --CH₂ --CH(CH₃)--CH₂ --R³. Additionally, he has developed a process for the enantiomer-selective preparation of γ-keto-δ-amino acid derivatives, involving a meticulous reaction process that converts specific compounds into desired cyclopropane structures, further illustrating his expertise in combinatorial chemistry and synthesis.

Career Highlights: Hans-Eckart Radunz is affiliated with Merck Patent Gesellschaft mit beschränkter Haftung, a leading pharmaceutical company known for its innovative contributions to the healthcare sector. His work at Merck has been instrumental in the advancement of various therapeutic agents, particularly in the area of immunomodulation and related fields.

Collaborations: Throughout his career, Radunz has collaborated with various experts in the industry, including notable coworkers Dieter Orth and Manfred Baumgarth. These collaborations emphasize the importance of teamwork in driving innovation and developing new, effective treatments to meet medical challenges.

Conclusion: Hans-Eckart Radunz's contributions to pharmaceutical patenting through his extensive patent portfolio underline his significant impact on the field of medicinal chemistry. His ongoing work continues to inspire innovation and enhance the development of key therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…